We chose the APP/PS1 mouse model of AD because it recapitulates the clinical characteristics of slow plaque development (27), which is more reflective of human AD pathogenesis and may provide a broader time window to allow monocyte entry. This evidence concerns the gene APP and Alzheimer disease.